Categories

Tag: Uncategorized

BLOGS: Alter-lanche

Wow, my hit counter is going crazy.  If you’re coming over from Eric Alterman’s blog, welcome & please take a look around.  This blog combines health care business and health care policy, and tries to tell the truth about the present, while highlighting big issues for the future. And in health care, the present is very, very messy. If you want more on health care policy, please fell free to peruse the policy and policy/politics categories on the left column — there’s plenty there for all types, but I am very cynical about the practical prospects for "market reform", particularly if it leaves out a large segment of the population.

PHARMA: Some funnies from the Pharma Marketing list-serv

Over on the pharma-mkting list serv there’s been some fun with those slighly misspelt words that make more sense than the original — apparently this started in the Washington Post’s Mensa Invitational.  Well the pharma marketing folks got into it and I saved them all meaning to compile  them on a rainy day.  John Mack has published these already over on his Pharma Marketing Blog but as we don’t share too many readers I thought some of you might like to see them. (I’ve also had them cluttering up my in-tray for a while and I’m up late uncluttering it! (Author is listed after definition).

Adhorence – deep hatred of advertising (John Mack)

Relationslip Marketing:  Establishing an initial connection with a consumer and then never doing anything meaningful with it.

Derail Aid:  A tool to confuse physicians (both David Reim)

DTC advertising: Direct to courthouse (James Gardner)

Salety Study: Which proves that the drug is worth selling, whether safe or not.

Generich Companies: Which make plenty of $ with somebody else’s innovations.

Phate III: Which concludes that the drug can be sold, the fate of a certain % of the target population being left to a higher power. (all Sanjay Virmani)

Charmaceutical:  An SSRI taken by someone who thinks they have a genuine diagnosis, but in reality are simply unpleasant.

Byotech:  A small, specialty pharmaceutical company whose stock rises paradoxically whenever they announce failed clinical trials.

Contrasindication:  A DTC ad deliberately designed to generate controversy, so as to get aired on cable news 10 times for every paid slot. (all Paul McNiven)

DTP-Direct to Plaintiff:  The art and science of creating plaintiffs with puffery enticing them to try dangereous drugs they would be better off without. (Terry Nugent)

Antibositics: Therapies undertaken to antagonise bosses’ criticism. (Kamran Shamsi)

Adverstising: The fine art of promoting adverse reactions through the use of realistic images of afflicted patients to target audiences consisting of physicians and consumers in a repulsive, yet memorable fashion. (Mario Nacinovich)

CEA: A term used to describe a ranking officer whose public utterances remind one of a pejorative or disdainful reference to a bodily part normally used to express intense disagreement with another’s expressed opinion. (Harry Sweeney)

Complieance — what patients tell their doctors about whether they are taking their pills (Me)

Pharmochondria: a morbid condition characterised by depressed spirits
and fancies of ill health induced by pharmaceutical "awareness"
campigns and advertising (Michael Lascelles)

and my favorite

Pharmasuitickle:- An overall pleasant tingling a personal trial attorney gets when contacted by a former Vioxx patient. (Jim Weidert)

And finally from Bob Iles (?), these are not misspellings but "daffynitions" from his Dictionary of Pharmaceutical Research.

Conclusions — What you designed your study to prove.

Informed consent — A document lawyers, doctors and administrators took weeks to write and revise but which a 100-IQ patient is expected to read, understand and sign within minutes before getting the drug, needle, knife and/or shaft.

Insight — The innate ability I have to see the clinical importance of my data. Called bias in those who disagree with me.

Null hypothesis — Conclusion you do not want to prove but which you strive mightily to reach. Makes as much sense as anything else in statistics.   

Strategy — The name you give after the fact to any series of random events that ended in your favor.

Statistics — [From Sanskrit "sadistics," meaning confounding verbiage] A means of getting people to argue about numbers instead of whether the test drug worked.

POLICY: Yet another shoddy article on single payer

The major outlets of the SCLM (so called liberal media) tend to give lots of column inches to conservatives like William Safire, Debra Saunders, and now Tucker Carlson on NPR and you don’t see the reciprocal placing of Michael Moore on Fox News or the Wall Street Journal. This week’s wingnut is Jeff Jacoby writing in the Boston Globe about how single payer would suck.  There may be a valid conversation about the merits of single payer, but this ain’t it. If the only people Jacoby can quote in his favor are the CDHP flacks at the NCPA and the appallingly biased Fraser Institute, he really needs to get a real education in this subject before he starts wasting column inches in a great newspaper.

Did he bother talking with anyone who knows something just across the Charles from Boston, like Bob Blendon or Marc Roberts at Harvard, both of whom are able to give an unbiased overview of the issues.  Did he even get America’s leading single payer advocate Steffi Woolhandler to tell her side of the story? It was all a cab ride away.  Even Bill O’Reilly’s had her on.

And he brought out a laundry list of where health care systems abroad are in trouble, and are resorting to rationing. No shit.  I can find him a much much longer list of bad things going on here, but why bother when the Wall Street Journal ran a whole series on rationing in the US in 2003.  Wasn’t Jacoby reading his fellow travelers’ stuff?  He never bothers to mention that the universal health care nations pay far less for their health care and get better population outcomes. Did he even know that?

This is a complex and difficult argument, but any rational analysis (like my rather good one about Canada!) shows that our system has at least as many problems as those abroad, and considerably more than those countries with a sensible public/private mix like France and Germany.

POLICY/POLITICS: Arnie, what a screw-up and what a disappointment

It’s incredible what a useless governor Arnie has been. Here was a guy from way outside the political establishment who had the chance to really change politics in California, so what has he done?

  1. He ran non-stop adverts all through the recall campaign saying that he would cut the state deficit by having a "full audit" (or in Arnie-speak "Foorl Ordit".  He then increased the deficit by canceling the $4bn increase to the car tax, and when, surprise, surprise, the Foorl Ordit didn’t miraculously find $15bn of waste to get rid of he simply borrowed the money by changing the law and issuing bonds.  Some budget hawk, eh.
  2. He ran as an outsider and used at least some of his own money in the campaign. But after  he won he paid his own account back from new political contributions — those are called bribes in less polite society — which came from not "special interests" like the ones from whom that Grey Davis guy used to get his cash from.  Oh no — Arnie’s money came from "powerful interests".  And who might they be?  Well apart from the Spanos real estate family that owns most of central California, it also includes a lot of money from big pharma after Arnie vetoed a bill trying to legalize Canadian imports into California.  No pay-off there
  3. And while we’re on the pay-off theme, several of us felt that the most despicable part of the Gray Davis regime was its ownership by the appalling prison guards union.  This is a state where a prison guard earns way, way more than a teacher, and where the CCOA (California Correctional Officers Association) in vehement on insisting that instead of spending money on education now instead of prisons later, we spend on prisons now and prisons later.  So a funny thing happens just before the Nov 2004 election. Arnie takes the prison guards cash, just like Davis did, and then comes out against the modest reform of the worst injustices of the 3-Strikes measure, turning it from a moderate winner to a very close loser — and costing the taxpayer a boatload more in the future.
  4. And to confirm his total moral bankruptcy, instead of standing as a decent Republican alternative to the clowns running the nation in DC, he decides to emulate them. While the Bush Administration has been putting out fake news stories and become a laughing stock along the way, now Arnie has decided to copy it.  What does this mean? Yes, you and I the taxpayer are paying for fake news propaganda to oppose the nurse staffing law which was passed with a fair measure of popular support, and was recently reaffirmed by a state judge.  And of course some dumb TV stations have been running the stories, which look like real news (in as much as "real news" is ever seen on local TV station news — I suspect the people who watch that stuff get the "news" they deserve.

There’s more fun stuff from www.Arnoldwatch.org including a fun video of protesters getting thrown out of an Arnie fundraiser.

BLOGS & BLOGGING: Excellent HIS blog

Somehow I’ve managed to miss until today the very interesting HIS talk blog, which has lots of nuggets about the health information systems business.

It’s been going as long as THCB, so I don’t know how I managed to avoid mention of it!

OFF-TOPIC: More dumbness in dealing with disgruntled ex-“employee”

Of so this one is not about the the Gadfly and Kaiser, or about health care at all.  but it is about another Bay Area institution being unnecessarily dragged into the press and the courts.  So Barry Bonds was having an affair (and I admit that I went to the story to check out what the girl looked like!).  And apparently he "forced" the woman to move to Arizona, sort of paid for her house down-payment and may have done that with money he didn’t pay tax on, and also told her that he took steroids before he later allegedly told a grand jury that he wasn’t taking steroids at that time. (Aren’t grand jury trials supposed to be secret?)  Here’s all the gory details along with some pictures of the protagonists (and I can see why Mr Bonds was interested!).

Apparently he mightily pissed her off, and then only offered her $20,000 to go away when she said that she’d lost $100,000 on the move to Arizona and had to become a bar-maid to make ends meet. So now she’s testifying to his perjury and she’s writing a book.  Given that she knew two potentially very damaging things about him, couldn’t someone in the Bonds’ empire have perhaps suggested to Barry that he ought to pay her to keep quiet. I suspect a few hundred thousand dollars in return for a confidentiality agreement would have been money very well spent out of Bonds’ $17m annual salary!  But like that other bay area institution KP (and for that matter that East Coast institution Martha Stewart), he’s happy to take huge risks for no apparent gain by not managing his dis-engagements properly. 

And what the hell was his superstar agent Scott Boras thinking in all this? I saw a talk he gave (and very dull it was too) where he said that he told Bonds in 1999 that he needed to improve his performance.  Perhaps it was that suggestion that got him on the juice in the first place? Shouldn’t Boras have been on tap to deal with this?

PHARMA/POLICY: Was Plan B Crawford’s ‘Plan B’ for Commissioner?

Ex-FDAer Robert Steeves has this fascinating look at how Lester Crawford made it to the FDA Commissioner’s office despite being largely responsible for the FDA’s lack of activity and failed response to the COX-2 acopalypse. This is a re-print from FDAweb, which I would encourage you to  subscribe to (although it’s not cheap so it’s probably best if someone else is picking up the tab!)  Thanks to FDA Web publisher Jim Dickinson for permission.  As you might suspect with this Administration, it looks like political payoffs have triumphed over scientific integrity and commonsense

Looks like the true story of Lester
Crawford
’s apparent triumph over conventional wisdom may be seeping out —
the only way most delicate information can get out of FDA. And it looks like a
good, old fashioned, political payoff. There are just too many “firsts” and too
many Plan B’s here to ignore.

Consider the emerging scenario as
follows:

In 2002, the White House considers Crawford for commissioner
and backs off for reasons never explained. Perhaps someone discovers that in
1985 the House Committee on Government Operations unanimously found that
then-CVM director Crawford “actually fostered the illegal marketing of
unapproved drugs,” failed to discourage the illegal use of drugs that tainted
the milk supply, failed to remove drugs from the market that had been proven
unsafe and approved drugs that his staff members suspected were carcinogenic.
Significantly, the committee found Crawford had disbanded an independent drug
safety group for humans within his Center because, as he then stated, “it is now
our job to approve drugs.” Internal reports warned that this move would
undermine safety concerns, hearings found.

Apparently concluding that Crawford could not be confirmed as FDA
commissioner in 2002, the White House instead names him deputy commissioner,
which many assume means de facto commissioner because popular wisdom is, and I
agree, that no nominee will be put up for confirmation to the top job. It makes
good sense — Senator Edward Kennedy,
the ranking Democrat on the Senate HELP Committee, has been threatening to
vigorously oppose any candidate with prior industry ties, and so placing
Crawford in a post not requiring confirmation avoids that obstacle without
changing substance. Anyway, FDA has no raging controversies and there are more
important issues facing the White House.

But FDA constituencies begin a steady drumbeat for a “permanent” FDA commissioner and
along comes Mark McClellan, a
physician with a business degree too, already serving in a presidentially
appointed and confirmed post, and he zips through the confirmation process but
sticks around for only 10 months before moving off to the Center for Medicare
and Medicaid Services. So, back to “Plan B” (leave Crawford as deputy and make
him the acting commissioner again.

Fast-forward to 2004 and the White House is looking at the potential of a
tough reelection race for the president, and there is unrest among the religious
and conservative base that Bush is not being sufficiently sensitive to their
concerns. Just when he needs least, Barr Laboratories provokes the
conservative/religious base with an NDA for an over-the-counter alleged
instant-abortion “morning after” pill, Plan B.

The nCDER review staff’s recommendation is favorable, the advisory committee agrees
23 to 4 and the decision gets kicked up a notch. CDER director Steven Galson “consults” with the Office of the Commissioner, FDA’s command center for political inputs. Why does
he do this, if as everyone later insists, the decision on Plan B is “purely
scientific” with no political considerations? He comes away from the
consultation and decides not to approve Plan B, saving the day for the White
House, intentionally or not.

To soften the blow for Barr, Galson suggests more “scientific” studies on the
“complex” question of how to assure that girls under 16 (not previously studied)
might handle Plan B and how to prevent them buying it if were available OTC.
Nobody but the religious far-right buys this subterfuge and political flak from
liberals gets into high gear as the election nears.

Meanwhile, the Vioxx withdrawal, the winter flu vaccine debacle,
whistleblower David Graham, and
associated pressures turn up even more heat on the White House for putting in a
permanent commissioner. Assessments on who the White House will nominate
universally discount him because he’s been the one in charge when the
controversies exploded, and because he has been passed over by the White House
before as being too provocative to the Kennedy crowd — notwithstanding the loyal
endorsement of his original champion, then HHS secretary and White House ally Tommy Thompson, or the rapidly
deteriorating situation at FDA under his management.

Wrong!!! Conventional wisdom forgets the “Plan B” political chit still
outstanding. When the president and the White House needed a “signal event” to
shore up the conservative base in the election campaign, who took the risk of
standing against the CDER drug review staff and the advisory committee’s
provocative recommendation — the first FDA head to do so that I can recall — and
save the day with the conservative base?
This is the scenario that is in the air. All the pieces make sense now and only if you
use all of these pieces. You do not have to have the political insights of a Karl Rove to put this together, but he might be a key witness in getting to the bottom of this.
When chairman Mike Enzi
reconvenes his Senate HELP Committee this week to examine the “unique and
confidential complexities” of Plan B, it ought be an open hearing, with sworn
witnesses.

What can be so secret about these machinations? To the extent that
there might be some trade secrets to protect, Barr CEO and chairman Bruce L. Downey — whose company surely has little to thank the Bush Administration for in this episode, given the profits lost by Plan B’s much-delayed launch — might waive any objections or
assertion of confidentiality, to permit the questions and explanations to be in
an open forum, especially if the witnesses risk perjury for false or misleading
statements. Mr. Downey has shown himself to be an innovative leader in the past
and he, too, might want to have this issue put to rest.
Is Plan B Crawford’s own “Plan B” route to the post that he lost in 2002 and that
conventional wisdom was sure he would otherwise have been denied? The Bush White
House values nothing higher than this kind of loyalty.

Neither science nor common sense can suggest any better explanation for this series of
decisions.

POLICY: Klepper on Porter

I’ve been in a healthy dialog with Brian Klepper and Pat Salber from the Center for Practical Health Reform in the last few weeks.  While I don’t agree with everything in their analysis, we have huge areas of common ground, and one part of that is in their view of Michael Porter’s thesis.  I wrote about this in THCB last year.  Here’s Brian Klepper’s response to Porter’s article.

A colleague recently commented on the similarities between CPHR’s work, and
Michael Porter’s and Elizabeth Teisberg’s recent Harvard Business Review article
on health care market competition. That led to the question of whether I had
contributed to their article. The question was passed to me, along with an
invitation to comment.
I rarely pass up such juicy invitations. Here’s
the short answer.

I did not contribute to the Porter/Teisberg piece. Michael
Porter is a well-established and highly respected thinker on markets. I have a
presentation with similar content he made a couple years ago; it’s clear he’s
been working on these health care concepts for a while.
But there’s more. When I read this new piece a few weeks ago, I had two thoughts.

One was that the article is a well thought through and accurate description of health
care’s two deepest problems: high fragmentation and a lack of systemic
management capability. In Porter’s and Teisberg’s zero-sum competition
framework, financial success is achieved more often through cost-shifting or
service reductions than efficiencies, and while organizations may benefit, the
larger enterprise rarely saves. In my work, I have described the same
circumstances, noting that in the highly fragmented HC marketplace, literally
thousands of organizations and millions of professionals pursue their
self-interests independent of their impacts on the whole. Fragmentation also
produces political gridlock that blocks change, because every potentially
positive reform gores somebody’s ox, and many groups have the power to kill any
proposal.

In the same vein, Porter/Teisberg talk in depth about the lack of the right
information in the right hands at the right time, and how that hinders the
ability of the health care marketplace to work properly and in everyone’s
interest. This, of course, restates the classic point made by the famous
economist Adam Smith, who said that markets can not work without perfect
information. CPHR has also relied on that point in its call for "standardized
management capability" in 4 areas: 1)universally compatible IT (which is the
predicate for systemic efficiencies), 2) standards (in the forms of
evidence-based medicine and management), 3) accountability/transparency at every
level of the system, and 4) technology assessment before innovations reach the
market and we begin to pay for them.

In
other words, my first thought was that Porter/Teisberg offer an insightful
explication of the system’s structural flaws. While they don’t really talk in
depth about current impacts, those flaws now appear to be effecting a
contraction in the health care economy that is unrelated to normal business
cycles.

But I differ with Drs. Porter and Teisberg on how we can effect
the changes that are so essential to improving competitiveness and fortifying
market stability. They offer a range of solutions, some of which mirror the
ideas our group has settled on (e.g., Transparency, A Minimum List of Coverage
Benefits), and others that are far more specific to certain industry sectors
(e.g., Simplified Billing, Non-Discriminatory Insurance Underwriting). In any
case, the authors appear to believe that once market players recognize the harm
caused by current dynamics, they will migrate to their solutions (or variations
on them). This, in turn, will improve competitiveness and bring the system back
to homeostasis. To me, this betrays two basic misunderstandings: one relates to
the trajectory of the current crisis, and the other to how power
works.

As a practical matter, we have come to believe that corporations
are the primary influencers of change in 21st Century America, and that health
care’s solutions lie at the convergence of the special and public interests. As
long as the system remains "normal" and unchanged, the traditional reform ideals
that Drs. Porter and Teisberg call for will be systematically blocked. For
example, employers will likely not buy into universal coverage if they believe
they’ll have to pay for it and if the cost continues to spiral up at seven times
general inflation. Health plans, physicians and hospitals will not likely agree
to transparency and performance accountability, for good and not-so-good reasons
associated with liability, exposure and profitability.

So if we want overcome gridlock and galvanize disparate interests toward a common vision of
change, a common value proposition is necessary. We must find something that
everyone, independent of perspective or special interest, can agree on and buy
into. And that agreement must be on something so powerful (and almost certainly,
alarming), that organizations will be willing to compromise their current
circumstances to achieve it.

We believe that value proposition is this. We are now witnessing a series of linked, rapidly intensifying economic phenomena that threaten the industry and the national economy. Porter and
Teisberg’s zero sum competition has generated a cost explosion that has driven
premium, where all cost converges, beyond a threshold of affordability for an
increasing percentage of individual, corporate and governmental purchasers.
(There’s lots of very compelling evidence for this, which I’ll be glad to
forward if anyone’s interested.) The shrinking commitment to coverage has
translated to an erosion of premium (masked by premium inflation), which in turn
constitutes a reduction in the total funds available to buy health care products
and services. This economic contraction could ultimately result in market
instability, the most feared of all market states, because in an environment of
significantly reduced resources and increasing demand, commerce grinds to a
halt. And that’s the thing that nobody wants to happen. Nobody wants health care
and its associated commerce to become immobilized.

And if health care,
the economy’s largest sector with 1 dollar in 7 and 1 job in 11, is disrupted,
then the chaos will almost certainly cascade to the larger US economy.

In recent months, CPHR has had many discussions with influential organizations
throughout health care and the broader business sector that have become
increasingly aware of the threat to corporate interests represented by impending
health care market instability. They have bought into the common value
proposition that instability must be averted, and they have agreed that our (and
to a large degree, Porter’s and Teisberg’s) principle set – informed
decision-making, universal basic coverage, and health care liability reform –
represents a narrowly defined set of structural (rather than philosophical)
principles that everyone in the system can abide, if they recognize that the
alternative is market instability.

In other words, the impetus for health care reform, in our view, is common self-interested buy-in by the nation’s most influential groups to the very severe threat posed by the economic implications
of current system flaws. The task then becomes mobilizing and positioning to
effect optimally positive change at the moment when the environment becomes
receptive to it.

To me, understanding health care’s current problems and
identifying solutions is not the hard part of the problem. Lots of people
seasoned in the industry have done this: The Institute of Medicine, Paul
Ellwood’s Jackson Hole Group, Dr. George Lundberg, the National Coalition on
Health Care (in the report they released last week), and so on. The harder part
is effecting change in a highly fragmented environment dominated by opposing
powerful interests. In my view, Dr. Porter and Teisberg handled the first part
very well but glossed over the latter part. Once CPHR became convinced that its
principles for change were refined and correct, we focused hardest on the latter
part, because that is the key to effectiveness, to the translation from idea to
action.

One last point. Drs. Porter and Teisberg really call for reform
that is based entirely on market-based solutions. They don’t frame their
solutions in terms of regulatory changes that can guide accelerated solutions
toward, for example, national standards (e.g., for IT compatibility, publicly
available performance information, minimum coverage) or rules of redress (in the
case of medical malpractice). In other words, they believe that organizations
will, on their own, execute programming that will be sufficient to resolve our
current problems and save the system.

We are less optimistic. Our argument would be that, at its heart, public policy should serve two important
purposes. First, it should protect the public from the overreaching grasp of
special interests (e.g., Enron). Second, in times of crisis, it should
facilitate a course correction that can save the system. Left to its own
devices, there is little evidence that the health care marketplace has the
organizational capability to effect enterprise-wide change that can avert market
instability. While new programs and tools (e.g., Disease Management,
Claims-Based Population-Level Management Tools, Patient-Decision Support Tools)
have the capacity to vastly improve our operations and effect savings, the
adjustments necessary to save America’s market-based health system require rapid
and pervasive implementation. This is one of those cases when the market simply
can’t do the job by itself. We need policy adjustment too.

BLOGS: THCB sells out!

Well not exactly, but I have taken a first tippy-toe in the commercial water by putting Google Ads down in the left column. No idea how it’ll play out but maybe I’ll cover some of my costs. Because of the nature of the program I have no control over the ads in it. Let me know what you think, and of course I’ll be reviewing it to see how it goes.  If you are interested in advertising/sponsoring the site, please let me know. (But I’m not expecting to get rich off this!)

Meanwhile, all of the back posts moved over from the old site have now been indexed into their correct category (doing that was a mind-numbing but  necessary task!).  So you should be able to see all the posts in a category that you’re interested in by clicking on the category in the left hand column.

assetto corsa mods